In June 2026, Dutch lithography leader ASML surpassed Novo Nordisk to become Europe’s most valuable company in history, with a market capitalization of $674 billion. This milestone is more than a financial record—it signals a tectonic shift in where global capital places its highest trust: from blockbuster biologics to irreplaceable semiconductor infrastructure.
ASML’s ascent rests on structural scarcity. In Q1 2026, it reported €8.8 billion in net sales and €2.8 billion in net income, with a gross margin of 53%. At the core is its near-monopoly on extreme ultraviolet (EUV) lithography. Every logic chip at 7nm and below—produced by TSMC, Samsung, or Intel—requires ASML’s EUV tools. The next-generation High-NA EUV systems, priced above €350 million each, have delivery lead times stretching to 18 months, with orders booked through 2028. This isn’t just strong demand; it’s technological indispensability.
Novo Nordisk’s decline from the top spot tells a contrasting story. Once hailed as the “Apple of biotech” for its GLP-1 drugs like Wegovy and Ozempic, the Danish firm now faces investor skepticism over growth sustainability. U.S. reimbursement uncertainties, looming biosimilar competition, and diminishing clinical marginal returns have triggered a 30% stock correction since early 2026. Its fall isn’t due to collapsing fundamentals but to the fragility of perfection-priced expectations.
The market cap handover reflects a deeper revaluation of growth paradigms. ASML embodies “bottleneck infrastructure”—a single point without which advanced computing halts. Novo Nordisk represents “consumption-driven therapeutics,” reliant on continuous clinical breakthroughs and market expansion. In an era defined by AI compute arms races, capital favors assets that gatekeep progress over those that merely benefit from it.
Geopolitics amplifies ASML’s strategic weight. U.S. export controls have forced ASML to suspend certain DUV shipments to China, affecting ~15% of its revenue but cementing its role as a technology chokepoint. Meanwhile, the EU’s €43 billion Chips Act aims to bolster regional supply chains, yet Europe lacks advanced logic fabs. ASML thus stands as the continent’s sole high-value node in the global semiconductor ecosystem—a position that makes it both indispensable to Western tech sovereignty and vulnerable to transatlantic policy friction.
Intel’s struggle offers another lens. The U.S. IDM giant’s 18A (1.8nm-equivalent) roadmap hinges entirely on timely High-NA EUV deliveries. Any delay jeopardizes its five-year plan to reclaim foundry leadership, revealing a paradox: even America’s most ambitious manufacturing revival cannot bypass a European equipment vendor.
TSMC in Taiwan, China, and Samsung in South Korea face similar dependencies. Their GAA transistor integration and advanced packaging roadmaps all presuppose ASML tool availability. The world’s three leading-edge foundries, despite fierce competition, share a single technological origin. This concentration delivers efficiency but incubates systemic risk: a disruption at ASML—whether from supply chain shocks, technical setbacks, or escalated sanctions—could freeze the entire advanced chip industry.
I judge ASML’s valuation peak not as an endpoint but as a warning flare in the restructuring of semiconductor power. Equipment makers are no longer support players; they now dictate the pace and boundaries of innovation. Yet this centrality carries peril. When one company holds the only key to future compute, diversity of innovation and resilience of supply chains erode.
Novo Nordisk’s retreat doesn’t diminish biotech’s long-term appeal. Instead, it underscores a new rule of value creation in volatile times: true moats aren’t built on how many customers you serve, but on whether others can function without you. ASML has mastered that calculus. But history cautions that monopolistic advantages are never permanent—whether disrupted by alternative technologies like nanoimprint lithography or by geopolitical fragmentation spawning parallel ecosystems. The higher Europe’s crown sits, the harder it may fall.